Henning Walczak

List of Publications by Year
in descending order

185 papers	35,416 citations	5782 84 h-index	4622 176 g-index
191 all docs	191 docs citations	191 times ranked	38341 citing authors

#	Article	IF	Citations
1	Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. Journal of Experimental Medicine, 2022, 219, .	4.2	35
2	Compound heterozygous variants in <i>OTULIN</i> are associated with fulminant atypical lateâ€onset ORAS. EMBO Molecular Medicine, 2022, 14, e14901.	3.3	14
3	Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARSâ€CoVâ€2 mRNA vaccination. EMBO Molecular Medicine, 2022, 14, .	3.3	7
4	TRAIL-receptor 2â€"a novel negative regulator of p53. Cell Death and Disease, 2021, 12, 757.	2.7	10
5	Dual roles for LUBAC signaling in thymic epithelial cell development and survival. Cell Death and Differentiation, 2021, 28, 2946-2956.	5.0	4
6	Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death and Differentiation, 2021, , .	5.0	10
7	An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. Cell Death Discovery, 2020, 6, 14.	2.0	18
8	Death Receptors and Their Ligands in Inflammatory Disease and Cancer. Cold Spring Harbor Perspectives in Biology, 2020, 12, a036384.	2.3	27
9	Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Molecular Cell, 2020, 77, 970-984.e7.	4.5	54
10	M1-linked ubiquitination by LUBEL is required for inflammatory responses to oral infection in Drosophila. Cell Death and Differentiation, 2019, 26, 860-876.	5.0	50
11	Linear ubiquitination at a glance. Journal of Cell Science, 2019, 132, .	1.2	65
12	Endothelial Cell Killing by TAK1 Inhibition: A Novel Anti-angiogenic Strategy in Cancer Therapy. Developmental Cell, 2019, 48, 127-128.	3.1	2
13	Cell Death and Inflammation â€" A Vital but Dangerous Liaison. Trends in Immunology, 2019, 40, 387-402.	2.9	73
14	RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. Cell Death and Differentiation, 2019, 26, 2710-2726.	5.0	23
15	LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. Nature, 2018, 557, 112-117.	13.7	168
16	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
17	Sterile Inflammation Fuels Gastric Cancer. Immunity, 2018, 48, 481-483.	6.6	7
18	Paving TRAILâ€™s Path with Ubiquitin. Trends in Biochemical Sciences, 2018, 43, 44-60.	3.7	32

#	Article	IF	Citations
19	TBK1 and IKKÎµ prevent TNF-induced cell death by RIPK1 phosphorylation. Nature Cell Biology, 2018, 20, 1389-1399.	4.6	198
20	LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L. Nature Communications, 2018, 9, 3910.	5.8	81
21	Characterization of the TNFR1-SC Using â€œModified Tandem Affinity Purificationâ€•in Conjunction with Liquid Chromatographyâ€“Mass Spectrometry (LC-MS). Methods in Molecular Biology, 2018, 1857, 161-169.	0.4	0
22	Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. ELife, 2018, 7, .	2.8	20
23	The Linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis. Hepatology, 2017, 65, 1963-1978.	3.6	29
24	The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Molecular Cell, 2017, 65, 730-742.e5.	4.5	189
25	The linear ubiquitin chain assembly complex regulates <scp>TRAIL</scp>â€•induced gene activation and cellÂdeath. EMBO Journal, 2017, 36, 1147-1166.	3.5	90
26	Martin Leverkus, 1965â€“2016. Cell Death Discovery, 2017, 3, 16093.	2.0	0
27	Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nature Reviews Cancer, 2017, 17, 352-366.	12.8	438
28	TLRs Go Linear â€“ On the Ubiquitin Edge. Trends in Molecular Medicine, 2017, 23, 296-309.	3.5	8
29	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell, 2017, 32, 342-359.e10.	7.7	122
30	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Scientific Reports, 2017, 7, 5514.	1.6	14
31	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Science Translational Medicine, 2017, 9, .	5.8	512
32	Zebrafish Model for Functional Screening of Flow-Responsive Genes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 130-143.	1.1	45
33	Mitochondrial permeabilization engages NF-ÎºB-dependent anti-tumour activity under caspaseÂdeficiency. Nature Cell Biology, 2017, 19, 1116-1129.	4.6	181
34	Opposing role of tumor necrosis factor receptor 1 signaling in T cellâ€“mediated hepatitis and bacterial infection in mice. Hepatology, 2016, 64, 508-521.	3.6	21
35	Formation and removal of polyâ€•ubiquitin chains in the regulation of tumor necrosis factorâ€•induced gene activation and cell death. FEBS Journal, 2016, 283, 2626-2639.	2.2	34
36	Poly-ubiquitination in TNFR1-mediated necroptosis. Cellular and Molecular Life Sciences, 2016, 73, 2165-2176.	2.4	130

#	Article	IF	Citations
37	SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. Cell Reports, 2016, 16, 2271-2280.	2.9	118
38	NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II. Cell Death and Disease, 2016, 7, e2346-e2346.	2.7	16
39	Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis. Nature Communications, 2016, 7, 13353.	5.8	47
40	ÂÂŁUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. Journal of Experimental Medicine, 2016, 213, 2671-2689.	4.2	79
41	NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-Î°B-Dependent and -Independent Functions. Immunity, 2016, 44, 553-567.	6.6	157
42	Holding RIPK1 on the Ubiquitin Leash in TNFR1 Signaling. Trends in Cell Biology, 2016, 26, 445-461.	3.6	146
43	Onto better TRAILs for cancer treatment. Cell Death and Differentiation, 2016, 23, 733-747.	5.0	259
44	Linear ubiquitination in immunity. Immunological Reviews, 2015, 266, 190-207.	2.8	124
45	LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes. Cell Reports, 2015, 13, 2258-2272.	2.9	238
46	WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma. Pathology Research and Practice, 2015, 211, 109-116.	1.0	11
47	UBE2L3 Polymorphism Amplifies NF-Î°B Activation and Promotes Plasma Cell Development, Linking Linear Ubiquitination to Multiple Autoimmune Diseases. American Journal of Human Genetics, 2015, 96, 221-234.	2.6	84
48	Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis. Cancer Cell, 2015, 27, 561-573.	7.7	173
49	Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus. Lancet, The, 2015, 385, S9.	6.3	15
50	The Schistosoma mansoni T2 ribonuclease omega-1 modulates inflammasome-dependent IL-1Î² secretion in macrophages. International Journal for Parasitology, 2015, 45, 809-813.	1.3	34
51	TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene, 2015, 34, 2138-2144.	2.6	65
52	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation, 2015, 22, 58-73.	5.0	811
53	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Oncotarget, 2015, 6, 10994-11008.	0.8	13
54	TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. ELife, 2014, 3, .	2.8	232

#	Article	IF	Citations
55	Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death and Differentiation, 2014, 21, 491-502.	5.0	100
56	Ubiquitin in the immune system. EMBO Reports, 2014, 15, 322-322.	2.0	4
57	Regulation of Death Receptor-Induced Necroptosis by Ubiquitination. , 2014, , 79-97.		0
58	Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1034-1046.	0.9	18
59	Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells. Gastroenterology, 2014, 146, 278-290.	0.6	101
60	Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nature Reviews Molecular Cell Biology, 2014, 15, 135-147.	16.1	1,373
61	Ubiquitin in the immune system. EMBO Reports, 2014, 15, 28-45.	2.0	193
62	Getting TRAIL back on track for cancer therapy. Cell Death and Differentiation, 2014, 21, 1350-1364.	5.0	392
63	Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathology Research and Practice, 2014, 210, 83-91.	1.0	9
64	HOIP Deficiency Causes Embryonic Lethality by Aberrant TNFR1-Mediated Endothelial Cell Death. Cell Reports, 2014, 9, 153-165.	2.9	217
65	Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer, 2013, 13, 532.	1.1	23
66	Necroptosis in Immunity and Ischemia-Reperfusion Injury. American Journal of Transplantation, 2013, 13, 2797-2804.	2.6	150
67	Apoptosis therapy: driving cancers down the road to ruin. Nature Medicine, 2013, 19, 131-133.	15.2	43
68	Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation. Cold Spring Harbor Perspectives in Biology, 2013, 5, a008698-a008698.	2.3	177
69	Linear ubiquitination: a newly discovered regulator of cell signalling. Trends in Biochemical Sciences, 2013, 38, 94-102.	3.7	133
70	Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death and Disease, 2013, 4, e719-e719.	2.7	129
71	Cezanne Regulates Inflammatory Responses to Hypoxia in Endothelial Cells by Targeting TRAF6 for Deubiquitination. Circulation Research, 2013, 112, 1583-1591.	2.0	51
72	Two independent pathways of regulated necrosis mediate ischemiaâ€“reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12024-12029.	3.3	485

#	Article	IF	Citations
73	No one can whistle a symphony alone â€" how different ubiquitin linkages cooperate to orchestrate NF-Î°B activity. Journal of Cell Science, 2012, 125, 549-559.	1.2	50
74	Thiocolchicoside a semiâ€synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption?. British Journal of Pharmacology, 2012, 165, 2124-2126.	2.7	7
75	The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity. Molecular Cell, 2012, 46, 746-758.	4.5	336
76	Generation and physiological roles of linear ubiquitin chains. BMC Biology, 2012, 10, 23.	1.7	143
77	Hypochlorite-modified low-density lipoprotein induces the apoptotic machinery in Jurkat T-cell lines. Biochemical and Biophysical Research Communications, 2011, 410, 895-900.	1.0	10
78	TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunological Reviews, 2011, 244, 9-28.	2.8	200
79	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	12.8	1,084
80	Linear ubiquitination prevents inflammation and regulates immune signalling. Nature, 2011, 471, 591-596.	13.7	805
81	Caspase-8 and Bid: Caught in the act between death receptors and mitochondria. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 558-563.	1.9	384
82	The Emerging Role of Linear Ubiquitination in Cell Signaling. Science Signaling, 2011, 4, re5.	1.6	64
83	The Linear Ubiquitin Chain Assembly Complex (LUBAC) Forms Part of the TNF-R1 Signalling Complex and Is Required for Effective TNF-Induced Gene Induction and Prevents TNF-Induced Apoptosis. Advances in Experimental Medicine and Biology, 2011, 691, 115-126.	0.8	13
84	TRAIL Dependent Fratricidal Killing of gp120 Primed Hepatocytes by HCV Core Expressing Hepatocytes. PLoS ONE, 2011, 6, e27171.	1.1	6
85	TRAIL-Rezeptor-Agonisten, eine neue Klasse proapoptotischer Krebstherapeutika. Onkopipeline, 2010, 3, 11-23.	0.0	0
86	Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. Journal of Neuro-Oncology, 2010, 97, 171-185.	1.4	16
87	Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFÎ°B activation via Src-dependent blockade of PP2A. Biochemical Pharmacology, 2010, 80, 439-447.	2.0	24
88	Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathology Research and Practice, 2010, 206, 43-50.	1.0	28
89	Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. Gastroenterology, 2010, 138, 2357-2367.	0.6	130
90	Polymeric Substrates with Tunable Elasticity and Nanoscopically Controlled Biomolecule Presentation. Langmuir, 2010, 26, 15472-15480.	1.6	75

#	Article	IF	Citations
91	Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. British Journal of Cancer, 2010, 102, 1707-1716.	2.9	70
92	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. Journal of Experimental Medicine, 2009, 206, 1379-1393.	4.2	39
93	TRAF2 Must Bind to Cellular Inhibitors of Apoptosis for Tumor Necrosis Factor (TNF) to Efficiently Activate NF-Î°B and to Prevent TNF-induced Apoptosis. Journal of Biological Chemistry, 2009, 284, 35906-35915.	1.6	202
94	Prognostic Value of Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. Clinical Cancer Research, 2009, 15, 650-659.	3.2	59
95	Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. Cancer Research, 2009, 69, 2425-2434.	0.4	140
96	From Biochemical Principles of Apoptosis Induction by TRAIL to Application in Tumour Therapy. Results and Problems in Cell Differentiation, 2009, 49, 115-143.	0.2	4
97	Is TRAIL the holy grail of cancer therapy?. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 607-623.	2.2	115
98	Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. Journal of Molecular Medicine, 2009, 87, 995-1007.	1.7	72
99	Microâ€Nanostructured Protein Arrays: A Tool for Geometrically Controlled Ligand Presentation. Small, 2009, 5, 1014-1018.	5.2	49
100	Following TRAILâ€™s path in the immune system. Immunology, 2009, 127, 145-154.	2.0	254
101	Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes the TNF-R1 Signaling Complex andÂIs Required for TNF-Mediated Gene Induction. Molecular Cell, 2009, 36, 831-844.	4.5	674
102	TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics. Advances in Experimental Medicine and Biology, 2009, 647, 195-206.	0.8	80
103	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. Journal of Cell Biology, 2009, 185, i13-i13.	2.3	0
104	Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene, 2008, 27, 3211-3220.	2.6	89
105	Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death and Differentiation, 2008, 15, 762-772.	5.0	191
106	NF-Î°B Inhibition Reveals Differential Mechanisms of TNF Versus TRAIL-Induced Apoptosis Upstream or at the Level of Caspase-8 Activation Independent of cIAP2. Journal of Investigative Dermatology, 2008, 128, 1134-1147.	0.3	61
107	Death receptors as targets for antiâ€cancer therapy. Journal of Cellular and Molecular Medicine, 2008, 12, 2566-2585.	1.6	58
108	Targeting XIAP Bypasses Bcl-2â€"Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth <i>In vitro</i> and <i>In vivo</i>. Cancer Research, 2008, 68, 7956-7965.	0.4	143

#	Article	IF	Citations
109	Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biology and Therapy, 2008, 7, 1982-1990.	1.5	14
110	Biochemical Analysis of the Native TRAIL Death-Inducing Signaling Complex. , 2008, 414, 221-239.		54
111	TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. Journal of Clinical Investigation, 2008, 118, 100-110.	3.9	159
112	Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. Clinical Cancer Research, 2007, 13, 6541-6542.	3.2	8
113	Lidocaine Induces Apoptosis via the Mitochondrial Pathway Independently of Death Receptor Signaling. Anesthesiology, 2007, 107, 136-143.	1.3	117
114	TRAIL signalling: Decisions between life and death. International Journal of Biochemistry and Cell Biology, 2007, 39, 1462-1475.	1.2	408
115	Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligandâ€"Induced Apoptosis. Clinical Cancer Research, 2007, 13, 3403-3412.	3.2	115
116	Protective effect of Mangifera indica L. polyphenols on human T lymphocytes against activation-induced cell death. Pharmacological Research, 2007, 55, 167-173.	3.1	26
117	Regulation of Enterocyte Apoptosis by Acyl-CoA Synthetase 5 Splicing. Gastroenterology, 2007, 133, 587-598.	0.6	47
118	TRAIL: a multifunctional cytokine. Frontiers in Bioscience - Landmark, 2007, 12, 3813.	3.0	114
119	TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 2007, 45, 649-658.	3.6	108
120	The promise of TRAILâ€"potential and risks of a novel anticancer therapy. Journal of Molecular Medicine, 2007, 85, 923-935.	1.7	175
121	TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiotherapy and Oncology, 2006, 80, 214-222.	0.3	34
122	Mangifera indica L. extract protects T cells from activation-induced cell death. International Immunopharmacology, 2006, 6, 1496-1505.	1.7	13
123	Caspases Target Only Two Architectural Components within the Core Structure of the Nuclear Pore Complex*. Journal of Biological Chemistry, 2006, 281, 1296-1304.	1.6	45
124	Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular Carcinoma. Cancer Research, 2006, 66, 7059-7066.	0.4	151
125	Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs. Clinical Cancer Research, 2006, 12, 2640-2646.	3.2	197
126	Transforming growth factor Î² can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology, 2005, 42, 183-192.	3.6	27

#	Article	IF	Citations
127	Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology, 2005, 42, 588-597.	3.6	165
128	cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-Î°B Activation at the Death-inducing Signaling Complex in Human Keratinocytes. Journal of Biological Chemistry, 2004, 279, 52824-52834.	1.6	46
129	NF-Î°B-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas/FasL Is Crucial for Efficient Influenza Virus Propagation. Journal of Biological Chemistry, 2004, 279, 30931-30937.	1.6	220
130	Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nature Medicine, 2004, 10, 389-395.	15.2	217
131	The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 125-132.	1.9	178
132	Activated Tâ€„killer cells induce apoptosis in lung epithelial cells and the release of pro-inflammatory cytokine TNF-Î±. European Journal of Immunology, 2004, 34, 1762-1770.	1.6	53
133	Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. International Journal of Cancer, 2004, 109, 281-290.	2.3	85
134	Apoptosis Induction by TRAIL. , 2003, 215, 95-116.		0
135	TRAIL-Induced Apoptosis and Gene Induction in HaCaT Keratinocytes: Differential Contribution of TRAIL Receptors 1 and 2. Journal of Investigative Dermatology, 2003, 121, 149-155.	0.3	59
136	In Chronic Pancreatitis, Widespread Emergence of TRAIL Receptors in Epithelia Coincides with Neoexpression of TRAIL by Pancreatic Stellate Cells of Early Fibrotic Areas. Laboratory Investigation, 2003, 83, 825-836.	1.7	32
137	Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation. Molecular and Cellular Biology, 2003, 23, 777-790.	1.1	109
138	TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus. Journal of Immunology, 2003, 170, 1814-1821.	0.4	97
139	CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. Journal of Clinical Investigation, 2003, 111, 1133-1145.	3.9	674
140	T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine, 2002, 8, 1433-1437.	15.2	149
141	Sensitive and real-time determination of H2O2 release from intact peroxisomes. Biochemical Journal, 2002, 363, 483.	1.7	29
142	Sensitive and real-time determination of H2O2 release from intact peroxisomes. Biochemical Journal, 2002, 363, 483-491.	1.7	48
143	TRAIL and its receptors in the colonic epithelium: A putative role in the defense of viral infections. Gastroenterology, 2002, 122, 659-666.	0.6	84
144	Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand But Presence of Its Receptors in the Human Brain. Journal of Neuroscience, 2002, 22, RC209-RC209.	1.7	106

#	Article	IF	Citations
145	TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. Cancer Gene Therapy, 2002, 9, 372-381.	2.2	21
146	Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO Journal, 2002, 21, 4520-4530.	3.5	303
147	T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine, 2002, 8, 1433-1437.	15.2	38
148	Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clinical Cancer Research, 2002, 8, 3734-40.	3.2	100
149	Targeting the Function of Mature Dendritic Cells by Human Cytomegalovirus. Immunity, 2001, 15, 997-1009.	6.6	203
150	CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene, 2001, 20, 4128-4137.	2.6	104
151	CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-Î°B contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene, 2001, 20, 4258-4269.	2.6	154
152	Biochemistry and function of the DISC. Trends in Biochemical Sciences, 2001, 26, 452-453.	3.7	64
153	Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5158-5163.	3.3	63
154	Critical role for mitochondria in B cell receptor-mediated apoptosis. European Journal of Immunology, 2000, 30, 69-77.	1.6	59
155	Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene, 2000, 19, 5477-5486.	2.6	257
156	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligandâ€“mediated apoptosis. Blood, 2000, 96, 2628-2631.	0.6	84
157	Cutting Edge: Resistance to Apoptosis and Continuous Proliferation of Dendritic Cells Deficient for TNF Receptor-1. Journal of Immunology, 2000, 165, 4792-4796.	0.4	31
158	Fluorogenic Substrates as Detectors of Caspase Activity During Natural Killer Cell-Induced Apoptosis. , 2000, 121, 155-162.		3
159	The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems. Experimental Cell Research, 2000, 256, 58-66.	1.2	586
160	FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2. Immunity, 2000, 12, 599-609.	6.6	748
161	Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Letters, 2000, 471, 93-98.	1.3	99
162	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligandâ€“mediated apoptosis. Blood, 2000, 96, 2628-2631.	0.6	10

#	Article	IF	Citations
163	Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Research, 2000, 60, 553-9.	0.4	244
164	Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Research, 2000, 60, 3051-7.	0.4	164
165	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood, 2000, 96, 2628-31.	0.6	27
166	Herpes Simplex Virus Type 1 Infection of Activated Cytotoxic T Cells. Journal of Experimental Medicine, 1999, 190, 1103-1114.	4.2	104
167	Tumoricidal activity of tumor necrosis factorâ€"related apoptosisâ€"inducing ligand in vivo. Nature Medicine, 1999, 5, 157-163.	15.2	2,377
168	Letter to the Editor. Cell Death and Differentiation, 1999, 6, 821-822.	5.0	75
169	CD95 Ligand (CD95L) in Normal Human Lymphoid Tissues. American Journal of Pathology, 1999, 154, 193-201.	1.9	36
170	We aim to refresh science, not to rebel. Nature, 1998, 393, 206-206.	13.7	0
171	A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation. European Journal of Immunology, 1998, 28, 2373-2383.	1.6	53
172	Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family. Journal of Experimental Medicine, 1997, 186, 1165-1170.	4.2	594
173	TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO Journal, 1997, 16, 5386-5397.	3.5	1,012
174	Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.. Journal of Clinical Investigation, 1997, 99, 403-413.	3.9	653
175	CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a pathologenetic role for the CD95/CD95 ligand-system in ulcerative colitis. Biochemical Society Transactions, 1996, 24, 614S-614S.	1.6	0
176	Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 1995, 373, 438-441.	13.7	1,625
177	Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature, 1995, 375, 497-500.	13.7	1,002
178	Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.. Journal of Experimental Medicine, 1995, 182, 1223-1230.	4.2	721
179	APO-1(CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. International Immunology, 1995, 7, 1873-1884.	1.8	64
180	Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death and Differentiation, 1995, 2, 163-71.	5.0	64

#	Article	IF	Citations
181	Cell nucleus and DNA fragmentation are not required for apoptosis.. Journal of Cell Biology, 1994, 127, 15-20.	2.3	419
182	Structure of the human APO-1 gene. European Journal of Immunology, 1994, 24, 3057-3062.	1.6	148
183	The Role of APO-1-Mediated Apoptosis in the Immune System. Immunological Reviews, 1994, 142, 175-191.	2.8	243
184	The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics, 1992, 14, 179-180.	1.3	47
185	Death Domainâ€“Containing Receptors â€“ Decisions between Suicide and Fire. , 0, , 23-36.		2